Bemcentinib in the context of first line metastatic melanoma treatment (NCT02872259) did not increase patient response or survival (57), and a first line combination treatment trial in STK11-mutant NSCLC was recently discontinued (NCT05469178, 58). This evidence concerns the gene STK11 and metastatic melanoma.